

Cooperative Activation of Gene Expression by Agonists and Antagonists Mediated by Estrogen Receptor Heteroligand Dimer Complexes

Shuang Liu, Sang Jun Han and Carolyn L Smith

Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX,
77030

Running title: Activation of gene expression by ER-heteroligand dimers

Corresponding author: Carolyn L Smith, PhD
Department of Molecular and Cellular Biology
Baylor College of Medicine
One Baylor Plaza
Houston, TX 77030
Email: carolyns@bcm.edu
Tel: 713-798-6235

Number of pages: 37

Number of figures: 8

Number of references: 55

Word count – Abstract: 227

Word count – Introduction: 730

Word count – Discussion: 1494

Abbreviations: AF-1, activation function-1; AF-2, activation function-2; BAZ, bazedoxifene; CE, conjugated estrogen; DBD, DNA binding domain; DR1, direct repeat spacing with 1bp; ER, estrogen receptor; ERE, estrogen response element; ER-HLD, ER α heteroligand dime; FXR, farnesoid X receptor; GRE, glucocorticoid response element; LBD, ligand binding domain; LXR, liver X receptor, NCoR, nuclear receptor corepressor; NR, nuclear receptor; pC3, promoter region of the human complement C3 gene; PPAR, peroxisome proliferator-activated receptor; RAR, retinoic acid receptor; RXR, retinoid X receptor, SERM, selective estrogen receptor modulator; SERD, selective estrogen receptor degraders; SRC, steroid receptor coactivator; TR, thyroid hormone receptor, TSEC, tissue selective estrogen complexes, VDR, vitamin D receptor.

Abstract

Estrogen receptor (ER) antagonists are generally thought to inhibit estrogen action through competitive inhibition resulting in receptor binding to antagonist rather than agonist. However, microarray analyses reveal a group of genes for which ER agonist and antagonist cooperatively regulate expression, suggesting additional models of combined agonist/antagonist action must exist. In conjunction with a chimeric reporter gene and two modified ERs, one [ER α (GSCKV)] with a mutation in the DNA binding domain and the other (ER α -G521R) with a ligand binding specificity mutation, we herein demonstrate that ER agonist and antagonist cooperatively active gene expression through an ER heteroligand dimer complex (ER-HLD) consisting of one subunit of the receptor dimer bound to agonist and another occupied by antagonist. Co-immunoprecipitation experiments confirmed interaction between the agonist-bound and antagonist-bound receptors. This cooperative activation of gene expression was enhanced by SRC-3 coactivator and required each ligand-bound subunit of the dimer to bind to DNA, as well as both activation function-1 domains for maximal transcriptional activity. Ligand combinations able to induce ER-HLD transcriptional activity include the agonists 17 β -estradiol or conjugated estrogens with the antagonists tamoxifen, raloxifene, bazedoxifene or fulvestrant. Moreover, ER-HLD can activate transcription in the context of a natural promoter. Taken together, this finding broadens our understanding of the complex relationship between ER agonist and antagonist, and suggests a novel model by which cell and tissue selective effects of antiestrogens may be achieved.

Introduction

Estrogen receptors (ERs) belong to the nuclear receptor (NR) superfamily of transcription factors and are modular proteins consisting of six domains designated A to F (Heldring et al., 2007). The A/B domain contains activation function-1 (AF-1) that influences transcriptional activity in a ligand-independent manner. The DNA binding domain (DBD, domain C) defines the response element specificity; while the ligand binding domain (LBD, domain E), mediates ligand binding, dimerization and contains a ligand-dependent transactivation function referred to as AF-2. The hinge region (domain D) is located between DBD and LBD, while the F domain is located at the extreme C-terminus. There are two ER genes, ER α and ER β , and the corresponding proteins share approximately 95% and 55% homology in the DBD and LBD, respectively (Thomas and Gustafsson, 2011). In the classical model, both receptors bind to estradiol with high affinity whereupon they undergo changes in conformation, dimerize either as homodimers (ER α /ER α or ER β /ER β) or heterodimers (ER α /ER β), bind to estrogen response elements (ERE) in the regulatory region of estrogen target genes and recruit coactivators to modulate gene expression (Thomas and Gustafsson, 2011;Heldring et al., 2007).

The biological functions of estrogens are important in many tissues including the breast, prostate, bone, brain and reproductive tract and pharmacological regulation of ER function is important in pre- and post-menopausal women. In addition to ER agonists such as 17 β -estradiol (E2), there are two classes of ER antagonists. The selective estrogen receptor modulators (SERMs) including tamoxifen, raloxifene and bazedoxifene exert estrogen-like and antiestrogen-like activities in a tissue selective manner, while the selective estrogen

receptor degraders (SERDs) such as ICI 182,780 downregulate ER α and inhibit ER function in most contexts. Agonists and antagonists for ER bind to the same site within the LBD (Shiau et al., 1998; Brzozowski et al., 1997) and antagonists are therefore able to competitively block estrogens from binding to the receptor and inducing gene expression. Moreover, antagonist-bound ERs adopt a distinct conformation that enables them to preferentially interact with corepressors rather than coactivators (Huang et al., 2010), thereby reinforcing their negative regulatory properties.

In contrast to the model of agonist and antagonist competing for binding to the LBD, ligand binding to heterodimeric NRs such as RXR partnered with either RAR, TR, VDR or PPAR, and regulation of their transcriptional activities is more complex (Pérez et al., 2012; Germain et al., 2006; Germain et al., 2002). Some heterodimers (PPAR/RXR, LXR/RXR, FXR/RXR) are “permissive” whereby a RXR-selective ligand (“rexinoid”) and a NR partner ligand can independently or synergistically activate the transcriptional activity of the heterodimer (Kliewer et al., 1992; Willy et al., 1995; Leblanc and Stunnenberg, 2012). In contrast, “non-permissive” heterodimers (including RAR/RXR, VDR/RXR and TR/RXR) are unresponsive to rexinoids alone and can only be stimulated by ligands that bind to the RXR partner receptor (Forman et al., 1995; Kurokawa et al., 1994; Westin et al., 1998) although rexinoids synergize with partner agonists to activate gene transcription when both ligands are present (Roy et al., 1995; Shulman et al., 2004). In addition, an RXR homodimer antagonist functions as an agonist when RXR is paired to specific partners, including PPAR and RAR (Lala et al., 1996). Thus, the ability of a given receptor ligand to activate or repress gene expression can be influenced by other ligands bound to the dimer partner.

Unlike RXR-associated heterodimers, ER α is generally thought to form homodimers bound to either agonist or antagonist depending upon the relative ligand concentrations. Thus, antiestrogens (e.g. tamoxifen) block E2 binding to ER α and antagonize estrogen-stimulated gene expression which is highly desirable relative to breast cancer prevention and treatment. However, recent MCF-7 breast cancer cell microarray experiments revealed a group of novel genes cooperatively regulated by ER α agonist and antagonist (Chang et al., 2010; Wardell et al., 2012). This is difficult to reconcile with competitive antagonism, and argues for an additional model for combined agonist/antagonist regulation of ER activity. Based on RXR heterodimer models, it was hypothesized that an antagonist within an ER α heteroligand dimer (ER-HLD) complex, consisting of antagonist-bound and agonist-bound ER α subunits, could stimulate rather than inhibit gene expression. To date, this possibility has not been addressed experimentally, particularly because regulating the binding of agonist and antagonist to homodimers is considerably more difficult than controlling the interaction of two different ligands to RXR-containing heterodimers. Nonetheless, this is an important question that has implications for the pharmacology of SERMs when used to inhibit ER α function in breast tissues where systemic and even locally produced estrogens may be present (Yaghjian and Colditz, 2011).

In order to evaluate whether antagonists could positively regulate the transcriptional activity of an ER-HLD complex, a chimeric luciferase reporter system was developed in conjunction with receptor mutations that regulate the specificity of ligand binding as well as DNA interaction. This model system demonstrates that ER α agonist and antagonist can cooperatively activate gene expression through an ER-HLD complex and has implications for understanding the molecular pharmacology of clinically important estrogen receptor

antagonists.

Materials and Methods

Cell Culture and Reagents

The HeLa human cervical carcinoma and HepG2 human hepatoma cell lines were obtained from American Type Culture Collection. HeLa cells were cultured in Dulbecco's Modified Eagle (DME) media containing 10% fetal bovine serum (FBS). HepG2 cells were maintained in minimum essential medium (MEM) supplemented with 10% FBS. 17 β -Estradiol, 4-hydroxytamoxifen and raloxifene were purchased from Sigma Chemical Company (St. Louis, MO). Bazedoxifene was provided by Pfizer Inc. (New York, NY). The pure antiestrogen ICI 182,780 was obtained from Tocris (Ellisville, MO). The mixture of the unconjugated forms of the 10 most abundant conjugated estrogen (CE) components of Premarin was prepared in the same relative proportions as is present in the Premarin formulation (Chang et al., 2010). Thus, a 1 mM CE stock solution was prepared from 1 mM solutions of each of the 10 components mixed proportionally according to their percentage ratios.

Plasmids

The expression plasmid pCR3.1-ER α and corresponding reporter gene ERE-e1b-Luc have been described previously (Nawaz et al., 1999a). The pCR3.1-ER α (G5CKV) plasmid was generated by PCR mutagenesis in which primers containing the DNA binding domain mutation region (5'-GGAAGCTGTAAAGTT-3') were used in two PCR reactions, generating ER cDNA fragments between the SmaI site and the mutation and between the mutation and the BglIII site. The two PCR products were then used as a template in a third PCR reaction to

create a fragment that was then digested with SmaI and BglII and subcloned back into the pCR3.1-ER α vector. The pCR3.1-ER α -G521R-Flag was generated by PCR with primers (5'-GGGGTACCCGGTCTGCACCCTGC-3' and 5'-CCGCTCGAGCGGACCGTGGCAGGGAA-3') using pCMV₅-ER α -G521R as a template (kindly provided by Dr. Benita Katzenellenbogen (Schodin et al., 1995)) and subcloned into pCR3.1 vector upstream of the sequence for a Flag epitope. The pcDNA3-ER α (GSCKV)-HA plasmid was generated by PCR with primers (5'-CGGAATTCCGGTCTGCACCCTGC-3' and 5'-CCGCTCGAGGACCGTGGCAGGGAA-3') using pCR3.1-ER α (GSCKV) as a template and subcloned into pcDNA3-HA vector (kindly provided by Dr. Hank H. Qi from Harvard Medical School, Boston, MA (Qi et al., 2010)). GRE-Luc and pC3-Luc have been described previously (Tzukerman et al., 1994; Nawaz et al., 1999b). The GGGTCacagTGACCT estrogen response element of ERE-e1b-Luc was mutated to GGGTCacagTGTTCT or TGTACacagTGACCT for the EGRE-e1b-Luc and the GERE-e1b-Luc reporter genes, respectively, by site directed mutagenesis. The $\frac{1}{2}$ ERE-Luc reporter was generated by mutating the GRE half site in EGRE-Luc construct from TGTTCT to TTTTTT by using mutagenesis primers (sense 5'-CTGCGATCTAAGTAAGCTTGGGTCACAGTTTTTTGATCAAAGTTAATGT-3' and antisense 5'-ACATTAACCTTTGATCAAAAACTGTGACCCAAGCTTACTTAGATCGCAG-3') following the instruction of Stratagene QuikChange® Site-Directed Mutagenesis Kit. The AF-1 mutant constructs 179C- ER α -G521R and 179C- ER α -GSCKV were generated by PCR amplifying the fragments of 179-595AA of the pCR3.1-ER α -G521R and

pCR3.1-ER α (GSCKV) vectors, respectively; and subcloning them into pCR3.1 vectors, respectively. All constructs were verified by DNA sequencing.

Luciferase Assay

For the HeLa cell line, 200,000 cells/well were seeded in 6-well plates in phenol red-free DME media containing 5% charcoal-stripped FBS (sFBS) one day before transfection. Cells were transfected with 1 μ g reporter gene and indicated amounts of expression vectors using Lipofectamine reagent (Invitrogen) in Opti-MEM (Invitrogen) following the manufacturer's instructions. Four to six hours later, Opti-MEM was replaced with phenol red-free DME media containing 5% sFBS. For the HepG2 cell line, 750,000 cells/well were seeded in 6-well plates in phenol red-free MEM supplemented with 10% sFBS. The next day media was removed. Cells were transfected with 1 μ g reporter gene and indicated amounts of expression vectors using Lipofectamine 2000 (Invitrogen) in Opti-MEM (Invitrogen) following the manufacturer's instructions. Four to six hours later, Opti-MEM was replaced with phenol red-free MEM supplemented with 10% sFBS. The following day, cells were treated with the indicated ligands at the specified concentrations, and 24 h thereafter were harvested using TEN buffer (40 mM Tris, pH 7.5, 150 mM NaCl and 1 mM EDTA). Cell pellets were resuspended in Reporter Lysis Buffer (Promega) and lysed according to the manufacturer's instructions. Luciferase activity was determined using a Luminoskan Ascent Microplate Luminometer (Thermo Labsystems) with Luciferase Assay Reagent (Promega) and normalized to protein concentration determined by Bio-Rad Protein Assay reagent (Bio-Rad Laboratories). All experiments were done in duplicate and repeated for three times.

Western blot

Cells were collected using TEN buffer and resuspended in ER extraction buffer (50 mM Tris, pH 8.0, 400 mM NaCl, 5 mM EDTA, 1% NP40, 0.2% Sarkosyl) supplemented with an EDTA-free Complete Mini protease inhibitor (Roche Applied Science, Indianapolis, IN). Cells were lysed on ice for 30 min after which protein concentrations were determined as above. Twenty micrograms of protein was mixed with LDS Sample Buffer containing Sample Reducing Agent (both Invitrogen), then heated to 75°C for 10 min. Proteins were separated using a 10% Bis-Tris gel and transferred in NuPAGE Transfer Buffer (Invitrogen) to a nitrocellulose membrane (GE Water & Process Technologies). The membrane was blocked in PBST (1×PBS plus 0.1% Tween-20) containing 5% dry milk powder (w/v). Primary antibodies were diluted in PBST with 1% milk powder and detected using HRP-conjugated secondary antibodies and the ECL Plus Western Blotting Detection System (both from GE Healthcare). Primary antibodies include ER α (HC-20, Santa Cruz Biotechnology), Actin (Clone C4, Millipore), anti-FLAG (F7425, Sigma) and HA (Y-11, Santa Cruz Biotechnology).

Co-immunoprecipitation

Following transfection, HeLa cells were cultured in phenol red-free DME media containing 5% sFBS for 48 h before treated with the indicated ligands for 1 h. Cells were harvested on ice in 1×PBS containing Complete Mini protease inhibitor (Roche). Cell pellets were lysed at 4 °C for 30 min in IP lysis buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and Complete Mini protease inhibitor), and lysate protein concentrations were determined as described above. One mg of lysate was pre-cleared for 2 h at 4 °C with 4 μ g

MOL #84228

mouse IgG and pre-washed protein G PLUS agarose beads (both from Santa Cruz Biotechnology) under constant rotation. Thereafter, lysates were incubated with 40 μ L anti-Flag M2 affinity gel suspension overnight at 4 °C. Immune complexes were washed four times with IP lysis buffer, then eluted using LDS sample buffer, and analyzed by Western blot analysis as described above.

Results

To test whether ER dimers in which each subunit binds to a different ligand can regulate gene expression in response to combined agonist/antagonist treatments, a chimeric receptor and reporter system was employed. First, a mutant form of ER α , ER α -G521R (Schodin et al., 1995) that possesses a ligand binding domain mutation permitting high affinity antagonist but not agonist binding was generated (**Fig. 1A**). As shown in **Fig. 1B**, estradiol (E2) and conjugated estrogens (CE) but not bazedoxifene (BAZ) activated wild-type ER α transcriptional activity measured by pC3-Luc reporter in HepG2 cells. In contrast, the ER α -G521R mutant was strongly activated by BAZ but not E2 or CE, demonstrating a complete change in the ligand specificity for inducing gene expression. Bazedoxifene was unable to increase pC3-Luc activity in cells co-transfected with pCR3.1 empty vector, indicating that the BAZ-induced luciferase expression was ER α -G521R-dependent (data not shown). The relative ability of CE and BAZ to regulate the transcriptional activity of ER α -G521R was further evaluated in dose response studies. Increasing concentrations of CE from 1 nM to 100 nM were unable to stimulate ER α -G521R activity, while BAZ stimulated the activity of ER α -G521R in a dose-responsive manner (**Fig. 1C**).

The second objective was to establish conditions where wild-type ER α would be activated by CE in the presence of a concentration of BAZ sufficient to activate ER α -G521R. A dose response study in cells transfected with wild-type ER α shows comparable activation of the pC3-Luc reporter gene by 1 to 100 nM CE, while BAZ failed to activate luciferase activity (**Fig. 1D**). As expected, BAZ activation of ER α -G521R was not influenced by co-treatment with CE, consistent with the inability of this receptor to be activated by estrogens (**Fig. 1E**). In contrast, antagonism studies demonstrated that BAZ at a concentration that is equal to or greater than the concentration of CE inhibited wild type ER α transcriptional activity (**Fig. 1F**). Thus, BAZ at a concentration of 1 nM or 10 nM does not

antagonize 10 nM CE or 100 nM CE induced wild-type ER α activity, respectively. Since 10 nM but not 1 nM BAZ was sufficient to activate ER α -G521R activity alone (Fig. 1C) or in combination with 1 to 100 nM CE (Fig. 1E), a combined treatment dosage of 100 nM CE and 10 nM BAZ was selected based on their abilities to effectively activate wild-type ER α and ER α -G521R, respectively.

Third, a DNA binding specificity mutation was introduced into wild-type ER α and a modified ER responsive reporter was generated. These chimeric reporter genes, GERE-Luc or EGRE-Luc consist of a luciferase cDNA downstream of a composite response elements consisting of a GRE half-site fused 5' to an ERE half-site and *vice versa* (Fig. 2A). To generate a receptor mutant able to bind to the GRE half-site, three amino acid residues located at the P-box, implicated in specific DNA interaction, in the first zinc finger module of the wild-type ER α DNA binding domain (DBD) were mutated to the corresponding amino acids in the glucocorticoid receptor (GR) DBD (Fig. 2B) thereby generating ER α (GSCKV) which had been shown previously to enable binding to GREs (Mader et al., 1989). Luciferase assays were employed to evaluate the function of ER α (GSCKV). As shown in Fig. 2C, ER α (GSCKV) was unable to activate ERE-Luc reporter activity in response to E2 or CE treatment while expression of the GRE-Luc reporter was strongly stimulated. This was consistent with prior testing reports (Tremblay et al., 1999). In contrast, wild-type ER α strongly stimulated expression of luciferase from the ERE-Luc but not the GRE-Luc reporter. To test whether wild type ER α and ER α (GSCKV) can work together to regulate the activity of the chimeric EGRE-Luc reporter, HepG2 cells were transfected with EGRE-Luc as well as wild type ER α and ER α (GSCKV), alone or in combination. As shown in Fig. 2D, 10 nM CE induced EGRE-Luc activity in the presence of either wild-type ER α or ER α (GSCKV) single receptor to a variable extent. However, greater activity was observed when both receptors

were co-expressed indicating that they work together to activate expression of the EGRE-Luc reporter.

With the successful generation of the chimeric reporter genes and receptor mutations, the ability of ER α dimers bound to agonist and antagonist to activate gene expression was tested. First, HepG2 cells were co-transfected with EGRE-Luc as well as ER α -G521R and ER α (GSCKV), alone or in combination (**Fig. 3A**). In cells expressing ER α -G521R, luciferase activity was stimulated by BAZ but not CE treatment, and CE+BAZ did not further increase luciferase. In cells expressing ER α (GSCKV), CE but not BAZ induced reporter activity, while the combination of CE and BAZ showed no further induction. When both forms of ER α were expressed in the cells, the combined CE+BAZ treatment induced maximal reporter gene expression while exposure to only agonist or antagonist yielded partial luciferase activity. The cooperative effect of CE+BAZ was also observed on the GERE-Luc reporter (**Fig. 3B**). In order to test whether this phenomenon is cell-type specific, similar luciferase assays were conducted in HeLa cells which demonstrated that combined CE and BAZ treatment induced greater activity of the chimeric reporters than either agent alone (**Fig. 3C**).

The above results indicate that ER α agonist and antagonist can work cooperatively to induce the maximal transcriptional activity. To test whether coactivators such as SRC-3, which are known to enhance ER α transcriptional activity (Suen et al., 1998), could enhance CE+BAZ stimulated expression of the chimeric reporter, HeLa cells were transfected with GERE-Luc, ER α -G521R and ER α (GSCKV) in the absence or presence of SRC-3 expression vector. Exogenous SRC-3 significantly enhanced CE+BAZ-induced luciferase activity, indicating that this coactivator can functionally interact with these receptors following combined agonist/antagonist treatment and suggesting a role for SRC-3 in mediating the gene

expression induced by this combined ligand treatment (**Fig. 3D**). Additionally, transfection of SRC-1 or SRC-2 can also boost the cooperative activation of CE+BAZ (data not shown). Lastly, to exclude the effect of differential receptor expression levels on reporter activity, Western blots were performed. HepG2 or HeLa cells transfected with single receptors [ER α -G521R or ER α (GSCKV)] expressed similar levels of receptor in comparison to ER α -G521R and ER α (GSCKV) co-transfected cells, indicating that the greater activity observed in the latter condition is not due to increased receptor expression (**Fig. 3E & F**). Taken together, the above data demonstrate the ability of an antagonist treatment to work together with agonist to activate gene expression in the chimeric model system. This cooperative effect requires the presence of both forms of receptor and can be co-activated by SRC-3.

To further characterize the ability of these receptors to mediate the cooperative effect of combined agonist/antagonist treatment, the ability of epitope tagged ER α -G521R-Flag and ER α (GSCKV)-HA receptors to interact with one another was tested in a co-immunoprecipitation assay. In cells treated with CE+BAZ, Flag antibody is able to immunoprecipitate ER α -G521R-Flag and ER α (GSCKV)-HA indicating an interaction between the receptors (**Fig. 4A**). A low level of interaction between the two forms of receptor is detected in the absence of any ligand, and is enhanced upon treatment with CE+BAZ (**Fig. 4B, compare lanes 5 to 6**), indicating that a complex can be formed between CE-bound ER α (GSCKV)-HA and BAZ-bound ER α -G521R-Flag *in vivo*. Receptor-receptor interaction was also promoted by BAZ alone (compare lanes 5 to 8), consistent with the ability of this ligand to bind to both receptors. In contrast, the interaction between ER α -G521R-Flag and ER α (GSCKV)-HA was inhibited by CE (compare lanes 5 to 7) presumably due to the ability of CE to promote formation of ER α (GSCKV)-HA homodimers and consequently reducing

the amount of this receptor available for heterodimer formation with ER α -G521R-Flag. To test whether the epitope-tagged receptors are functional, HeLa cells transfected with GERE-Luc, ER α -G521R-Flag and ER α (GSCKV)-HA were treated with CE and BAZ, alone or in combination. The epitope tagged vectors were similar to ER α -G521R and ER α (GSCKV) in their ability to cooperatively activate luciferase activity in response to CE+BAZ treatment (data not shown). These data demonstrate the possibility that agonist-bound ER α (GSCKV)-HA and antagonist-bound ER α -G521R can form a ER α heteroligand dimer (ER α -HLD) complex in cells that can cooperatively stimulate gene expression.

In order to test whether the CE+BAZ cooperative activation of chimeric reporter activity requires each monomer within the ER α -HLD to bind to DNA, a $\frac{1}{2}$ ERE-Luc reporter was generated in which the GRE half-site of the chimeric reporter was mutated. Activities induced by CE+BAZ treatment in cells transfected with ER α -G521R and ER α (GSCKV) were compared for the $\frac{1}{2}$ ERE-Luc *versus* the EGRE-Luc reporter (**Fig. 5A & B**). No cooperative effect of CE+BAZ treatment was observed for the $\frac{1}{2}$ ERE-Luc reporter in either HepG2 or HeLa cells. This indicates that CE-bound ER α (GSCKV) and BAZ-bound ER α -G521R must both bind to DNA to cooperatively activate gene expression, rather than a single receptor binding to the ERE half site and interacting with a non-DNA binding receptor partner solely via protein-protein interactions.

As the agonist activity of SERMs is dependent on AF-1 activity (Berry et al., 1990), the role of each receptor's AF-1 domain on the activity achieved by the ER α -HLD complex was evaluated on the EGRE-Luc and GERE-Luc reporters. Deletion of the AF-1 domain of either of the ER α receptors attenuated the cooperative effect of CE+BAZ, regardless of the order in which the receptors bound to the target gene (**Fig. 6A & B**). Moreover, removal of both AF-1 domains from the heteroligand dimer complex completely blocked the ability of

CE+BAZ to stimulate luciferase gene expression, indicating that the AF-1 domains from each ER α subunit make important contributions to the transcriptional activity of the ER α heteroligand dimer.

To extend these observations beyond the chimeric reporter model system, the ability of CE+BAZ to cooperatively activate a reporter gene regulated by a natural ER α target promoter was investigated. HepG2 cells were co-transfected with the pC3-Luc reporter, consisting of the complement 3 promoter linked to luciferase (Tzukerman et al., 1994) along with wild-type ER α and ER α -G521R, alone or in combination. For cells expressing only wild-type ER α or ER α -G521R, the activity from CE or BAZ single treatment was equivalent to the CE+BAZ combination treatment (**Fig. 7**). However, when both receptors are co-expressed, luciferase activity is greater in cells treated with CE+BAZ than either of the single ligands alone. These data clearly indicate that CE-bound wild-type ER α and BAZ-bound ER α -G521R can cooperatively work to promote a transcriptional response.

In addition to the combination of CE and BAZ, the ability of different combinations of estrogens and SERMs to cooperatively activate expression of the chimeric reporter was tested. As shown in **Fig. 8A**, E2 cooperated with BAZ to stimulate the activity of the GERE-Luc reporters in HeLa cells at a level comparable to CE+BAZ combined treatment indicating that estradiol, the most potent naturally occurring estrogen, can work in combination with antagonists to induce gene expression. This effect is not limited to BAZ as CE could cooperate with a variety of SERMs including 4-hydroxytamoxifen, raloxifene and ICI 182,780 to activate gene expression (**Fig. 8B**). Similar amounts of receptor expression were detected for all treatment groups, indicating that the greater activities in the combination conditions are not due to a corresponding change in receptor levels (**Fig. 8B, inset**). Thus, these data indicate that the agonist/antagonist cooperative transcriptional effects mediated by

MOL #84228

an ER α heteroligand dimer complex can be achieved by a variety of estrogen and anti-estrogen combinations.

Discussion

ER antagonists are generally thought to inhibit estrogen action through a competitive mechanism. However, microarray analyses reveal a group of genes for which ER agonist and antagonist cooperatively regulate expression, suggesting additional models of combined agonist/antagonist action must exist (Chang et al., 2010; Wardell et al., 2012). We herein demonstrate that ER agonist/antagonist combined treatment can cooperatively activate gene expression through an ER-HLD complex consisting of one receptor monomer bound to agonist and another occupied by antagonist. This cooperative activation of gene expression can be enhanced by SRC-3 coactivator, requires both ligand-bound subunits to bind to DNA and both AF-1 domains within the ER-HLD for maximal transcriptional activity. Moreover, ER-HLD complexes can activate transcription in the context of a natural promoter, and taken together demonstrates that ERs bound to different classes of ligands can form dimers that promote gene expression.

The ability of the CE-bound ER α (G521R)-HA and BAZ-bound ER α -G521R-Flag to form a dimer complex in cells, as demonstrated by co-immunoprecipitation experiments, revealed a weak level of basal interaction that was significantly enhanced upon treatment with CE+BAZ. This is analogous to the ability of wild-type ER α to exist as a dimer in the absence of ligand and for E2 to promote dimer interaction (Tamrazi et al., 2002). Individual ER subunits come together to form dimers through two domains, one in the DBD and a second in the LBD (Bai and Gust, 2009). The weak dimerization interface located in the DBD is ligand-independent and responsible for the selection of the spacing distance between the two ERE half-sites (Bai and Gust, 2009; Kuntz and Shapiro, 1997). The latter constitutes

the principal ER α dimerization interface with head-to-head contacts between the two subunits mediated primarily through helix 11 (H11) to H11 interactions (Shiau et al., 1998;Brzozowski et al., 1997). Crystal structures of the ER α LBDs bound to either E2 or raloxifene reveal that both ligands bind to the same pocket, and that the overall homodimeric arrangement is the same regardless of whether the LBD is agonist or antagonist bound (Shiau et al., 1998;Brzozowski et al., 1997). Indeed, with the possible exception of ICI-bound ER α , the relative monomer orientation at the H11 dimer interface does not vary substantially for receptors bound to agonist or antagonist (Pike et al., 2001), and it is therefore reasonable that these interaction surfaces can mediate dimer formation even when each subunit is occupied by a different ligand.

Through the use of chimeric reporters which directed CE-bound ER α (GSCKV) to bind to DNA either upstream or downstream of the BAZ-bound ER α -G521R, we were able to demonstrate that the relative position of the receptors does not impact cooperative activation by combined agonist/antagonist treatment. This is different from RXR-associated heterodimers in which the polarity of receptor binding to DNA impacts transcriptional activity (Orlov et al., 2012;Jimenez-Lara and Aranda, 1999;Chandra et al., 2008). For direct repeat (DR) response elements, RXR is generally located on the upstream half-site and this arrangement permits the ligand-bound NR partner to attain an active conformation that facilitates coactivator recruitment (Mangelsdorf and Evans, 1995;Orlov et al., 2012). However, the RAR/RXR heterodimer binds to DNA with a reversed polarity on DR1 (direct repeat spacing with 1bp) response elements, and in most contexts this heterodimer constitutively represses transcription because the NCoR corepressor remains associated with

the RAR/RXR heterodimer even in the presence of RAR or RXR ligands (Kurokawa et al., 1994;Kurokawa et al., 1995). Thus, RAR/RXR experiments suggest that the relative orientation of half-sites within the response element can allosterically regulate receptor interaction with coregulators leading to either activation or repression of gene expression, but this is not the case for ER-HLDs since they interacted with SRC-3 coactivator and induced gene expression in both DNA-binding orientations.

In the classical model for ER dimers binding to EREs, each receptor partner binds to one of the ERE half-sites with the 3-bp spacer influencing stability of the dimer interface and DNA binding specificity (Schwabe et al., 1993b;Schwabe et al., 1993a). In contrast, evidence from multiple whole genome studies indicates that a majority of ER α binding sites do not correspond to consensus EREs but rather encompass one or more half-site EREs (Carroll et al., 2005;Lin et al., 2007). This was somewhat surprising as individual half EREs were considered to be non-functional because early *in vitro* binding experiments including EMSA assays did not detect binding to these half-sites (Klinge, 2001). However, a recent report demonstrates ER α binding to half-site EREs, particularly in conjunction with elevated high-mobility group protein B1 expression, and stimulation of luciferase reporter activity (Joshi et al., 2011). Our data also indicate that ER α can weakly activate gene transcription through a half-site ERE site in response to ligand treatment, but without a cooperative effect of combined agonist/antagonist treatment indicating that effective ER-HLD promotion of gene expression requires both ER subunits to bind to DNA rather than one receptor tethering a second ER molecule to the gene. Whether ER-HLD can mediate transcriptional effects via multiple half-site EREs, as have been found in numerous genes,

remains to be determined.

Activation of gene expression by ERs is dependent upon coactivators, such as SRC family coactivators, which make their primary contact through interaction of one or more LXXLL motifs with the AF-2 domain of agonist-bound receptors (Heery et al., 1997). Conversely, antagonist-bound ER α adapts a conformation in which the LXXLL-like sequence within helix H12 binds against the coactivator docking surface and thereby prevents coactivators from effectively binding to receptor (Shiau et al., 1998). It has been reported that SRC-1 and SRC-2 bind to the liganded ER α LBD with a stoichiometry of one coactivator per homodimer (Margeat et al., 2001;Osz et al., 2012), and a similar mode of binding was observed for SRC-1 and SRC-2 binding to RAR-RXR heterodimers (Osz et al., 2012). Moreover, 1,25-dihydroxyvitamin D₃ and 9-cis-retinoic acid synergistically activate VDR/RXR heterodimers by facilitating a concerted interaction between both receptors with distinct NR boxes of one molecule of SRC-1 (Zhang et al., 2011). Enhancement of agonist/antagonist-stimulated ER-HLD activity by SRC-3 indicates that this coactivator can interact with the heteroliganded dimer to active gene expression. While it is highly likely that SRC-3 binds to the agonist-bound LBD, it is less certain that this coactivator can bind to antagonist-bound ER-G521R and whether one molecule of SRC-3 can bind to the LBD of each member of the ER-HLD is therefore unclear.

Relative to co-stimulation by agonist/antagonist, the AF-1 domain is important for the partial agonist activity of SERMs such as tamoxifen (McInerney et al., 1996), and SRC-1 can bind to both the AF-1 and AF-2 domains of ER α through the coactivator's Q-rich region and LXXLL motifs, respectively (Mérot et al., 2004). This raises the possibility that SRC-3

interacts with ER-HLDs through different AF domains on distinct subunits (*e.g.* AF-2 on agonist-bound ER(GSCKV) and AF-1 on antagonist-bound ER-G521R) to induce maximal transcriptional activity. Indeed, while our data revealed that AF-1 deletion for either ER α -G521R or ER α (GSCKV) attenuated transcriptional activity, loss of a single AF-1 domain had a greater impact on the ER α -G521R than the ER α (GSCKV) receptor, suggesting a greater dependence on AF-1 activity by the former component of the ER-HLD. The near complete loss of transcriptional activity when both AF-1 domains were deleted further demonstrates the importance of the AF-1 region to ER-HLD transcriptional activity, and suggests that ER-HLD activity may be more prominent in cell and tissue environments favorable to AF-1 activity (*e.g.* during elevated growth factor signaling).

Agonist and antagonist combinations can cooperatively activate gene expression mediated through ER-HLDs on chimeric reporter genes as well as on a target gene regulated by a natural promoter, indicating the potential of this novel mode of ER α function to regulate endogenous gene expression. Two recent microarray experiments demonstrate that in MCF-7 cells treated with estrogen and SERMs, alone or in combination, there is a subset of genes induced to a greater extent by combined estrogen and SERM treatment than by either single agent (Chang et al., 2010;Wardell et al., 2012). The ability of ER-HLD to cooperatively regulate gene expression induced by combined agonist/antagonist treatments provides a possible mechanistic explanation for the induction rather than the inhibition of the expression of these genes. On a global level, the features of these potential ER-HLD regulated genes that enables antagonists to cooperate with, rather than antagonize agonists in the stimulation of their expression are unknown. Of potential significance, the existing gene microarray data

also reveal unique gene sets induced by different antagonist/estrogen combinations, suggesting that the regulatory (*e.g.* promoter) regions of endogenous genes encode information that enables differential responses to distinct ER-HLD complexes (*e.g.* following bazedoxifene/estrogen *versus* raloxifene/estrogen exposure) perhaps through alterations in ER-HLD conformation and resultant recruitment of distinct coactivator complexes.

Our novel finding of ER-HLD mediating the cooperative effect of ER agonist and antagonist within a dimer context not only broadens our understanding of the complex mechanisms of action of ER agonists and antagonists, but also is of significant clinical interest. Combined administration of a SERM and an estrogen has been evaluated clinically, and these tissue selective estrogen complexes (TSECs) alleviate post-menopausal symptoms without the increased risks associated with estrogen monotherapy (Archer, 2010;Lobo et al., 2009;Lindsay, 2011;Pinkerton et al., 2009). In addition, the well-established use of ER antagonists such as tamoxifen for breast cancer prevention and treatment is based on their demonstrated ability to inhibit E2-induced effects as well as their clinical efficacy (Osborne, 2012). Thus, antagonists are routinely employed in settings where endogenous estrogens, be they systemic or locally produced by breast and/or tumor cells (Yaghjyan and Colditz, 2011), are available to generate ER-HLD complexes. The contribution of these types of complexes to the *in vivo* biological activities of ER antagonists remains to be fully elucidated, but these data suggest a potential role for ER-HLDs in the gene-, cell- and tissue-specific of SERMs and TSECs, as well as the ability of breast tumors to become resistant to SERM therapies.

Acknowledgements

The authors thank Patricia Dillard and Joe Roethele for technical assistance, and Dr. Benita Katzenellenbogen for providing materials.

Authorship Contributions

Participated in research design: Shuang Liu, Carolyn L Smith

Conducted experiments: Shuang Liu

Contributed new agents or analytic tools: Sang Jun Han

Performed data analysis: Shuang Liu, Carolyn L Smith

Wrote and contributed to the writing of the manuscript: Shuang Liu, Carolyn L Smith

References

- Archer DF (2010) Tissue-Selective Estrogen Complexes: a Promising Option for the Comprehensive Management of Menopausal Symptoms. *Drugs Aging* **27**:533-544.
- Bai Z and Gust R (2009) Breast Cancer, Estrogen Receptor and Ligands. *Arch Pharm Chem Life Sci* **342**:133-149.
- Berry M, Metzger D and Chambon P (1990) Role of the Two Activating Domains of the Oestrogen Receptor in the Cell-Type and Promoter-Context Dependent Agonistic Activity of the Anti-Oestrogen 4-Hydroxytamoxifen. *EMBO J* **9**:2811-2812.
- Brzozowski AM, Pike A C, Dauter Z, Hubbard R E, Bonn T, Engstrom O, Ohman L, Greene G L, Gustafsson J-Å and Carlquist M (1997) Molecular Basis of Agonism and Antagonism in the Oestrogen Receptor. *Nature* **389**:753-758.
- Carroll JS, Liu X S, Brodsky A S, Li W, Meyer C A, Szary A J, Eeckhoute J, Shao W, Hestermann E V, Geistlinger T R, Fox E A, Silver P A and Brown M (2005) Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1. *Cell* **122**:33-43.
- Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris T P and Rastinejad F (2008) Structure of the Intact PPAR- γ -RXR- α Nuclear Receptor Complex on DNA. *Nature* **456**:350-356.
- Chang KCN, Wang Y, Bodine P V N, Nagpal S and Komm B S (2010) Gene Expression Profiling Studies of Three SERMS and Their Conjugated Estrogen Combinations in Human Breast Cancer Cells: Insights into the Unique Antagonistic Effects of Bazedoxifene on Conjugated Estrogens. *J Steroid Biochem Mol Biol* **118**:117-124.
- Forman BM, Umesono K, Chen J and Evans R M (1995) Unique Response Pathways Are Established by Allosteric Interactions Among Nuclear Hormone Receptors. *Cell* **81**:541-550.
- Germain P, Chambon P, Eichele G, Evans R M, Lazar M A, Leid M, de Lera A R, Lotan R, Mangelsdorf D J and Gronemeyer H (2006) International Union of Pharmacology. LXIII. Retinoid X Receptors. *Pharmacological Reviews* **58**:760-772.
- Germain P, Iyer J, Zechel C and Gronemeyer H (2002) Co-Regulator Recruitment and the Mechanism of Retinoic Acid Receptor Synergy. *Nature* **415**:187-192.
- Heery DM, Kalkhoven E, Hoare S and Parker M G (1997) A Signature Motif in Transcriptional Co-Activators Mediates Binding to Nuclear Receptors. *Nature* **387**:733-736.
- Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M and Gustafsson J-Å (2007) Estrogen Receptors: How Do They Signal and What Are Their Targets. *Physiol Rev* **87**:905-931.
- Huang P, Chandra V and Rastinejad F (2010) Structural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics. *Annu Rev Physiol* **72**:247-272.
- Jimenez-Lara AM and Aranda A (1999) The Vitamin D Receptor Binds in a Transcriptionally Inactive Form and Without a Defined Polarity on a Retinoic Acid Response Element. *FASEB*

J **13**:1073-1081.

Joshi SR, Ghattamaneni R B and Scovell W M (2011) Expanding the Paradigm for Estrogen Receptor Binding and Transcriptional Activation. *Mol Endocrinol* **25**:980-994.

Kliwer SA, Umesono K, Noonan D J, Heyman R A and Evans R M (1992) Convergence of 9-*Cis* Retinoic Acid and Peroxisome Proliferator Signalling Pathways Through Heterodimer Formation of Their Receptors. *Nature* **358**:771-774.

Klinge CM (2001) Estrogen Receptor Interaction With Estrogen Response Elements. *Nucl Acid Res* **29**:2905-2919.

Kuntz MA and Shapiro D J (1997) Dimerizing the Estrogen Receptor DNA Binding Domain Enhances Binding to Estrogen Response Elements. *J Biol Chem* **272**:27949-27956.

Kurokawa R, DiRenzo J, Boehm M, Sugarman J, Glass B, Rosenfeld M G, Heyman R A and Glass C K (1994) Regulation of Retinoid Signaling by Receptor Polarity and Allosteric Control of Ligand Binding. *Nature* **371**:528-531.

Kurokawa R, Soderstrom M, Horlein A, Halachmi S, Brown M, Rosenfeld M G and Glass C K (1995) Polarity-Specific Activities of Retinoic Acid Receptors Determined by a Co-Repressor. *Nature* **377**:451-454.

Lala DS, Mukherjee R, Schulman I G, Koch S S C, Dardashti L J, Nadzan A M, Croston G E, Evans R M and Heyman R A (1996) Activation of Specific RXR Heterodimers by an Antagonist of RXR Homodimers. *Nature* **383**:450-453.

Leblanc BP and Stunnenberg H G (2012) 9-*Cis* Retinoic Acid Signaling: Changing Partners Causes Some Excitement. *Genes Dev* **9**:1811-1816.

Lin C-Y, Vega V B, Thomsen J S, Zhang T, Kong S L, Xie M, Chiu K P, Lipovich L, Barnett D H, Stossi F, Yeo A, George J, Kuznetsov V A, Lee Y K, Charn T H, Palanisamy N, Miller L D, Cheung E, Katzenellenbogen B S, Ruan Y, Bourque G, Wei C L and Liu E T (2007) Whole-Genome Cartography of Estrogen Receptor α Binding Sites. *PLoS Genet* **3**:e87.

Lindsay R (2011) Preventing Osteoporosis With a Tissue Selective Estrogen Complex (TSEC) Containing Bazedoxifene/Conjugated Estrogens (BZA/CE). *Osteoporos* **22**:447-451.

Lobo RA, Pinkerton J V, Gass M L S, Dorin M H, Ronkin S, Pickar J H and Constantine G (2009) Evaluation of Bazedoxifene/Conjugated Estrogens for the Treatment of Menopausal Symptoms and Effects on Metabolic Parameters and Overall Safety Profile. *Fertil Steril* **92**:1025-1038.

Mader S, Kumar V, deVerneuil H and Chambon P (1989) Three Amino Acids of the Oestrogen Receptor Are Essential to Its Ability to Distinguish an Oestrogen From a Glucocorticoid-Responsive Element. *Nature* **338**:271-274.

Mangelsdorf DJ and Evans R M (1995) The RXR Heterodimers and Orphan Receptors. *Cell* **83**:841-850.

Margeat E, Poujol N, Boulahtouf A, Chen Y, Müller J D, Gratton E, Cavailles V and Royer C A (2001) The Human Estrogen Receptor α Dimer Binds a Single SRC-1 Coactivator Molecule With an Affinity Dictated by Agonist Structure. *J Mol Biol* **306**:433-442.

- McInerney EM, Tsai M-J, O'Malley B W and Katzenellenbogen B S (1996) Analysis of Estrogen Receptor Transcriptional Enhancement by a Nuclear Hormone Receptor Coactivator. *Proc Natl Acad Sci USA* **93**:10069-10073.
- Mérot Y, Métivier R, Penot G, Manu D, Saligaut C, Gannon F, Pakdel F, Kah O and Flouriot G (2004) The Relative Contribution Exerted by AF-1 and AF-2 Transactivation Functions in Estrogen Receptor α Transcriptional Activity Depends Upon the Differentiation Stage of the Cell. *J Biol Chem* **279**:26184-26191.
- Nawaz Z, Lonard D M, Dennis A P, Smith C L and O'Malley B W (1999a) Proteasome-Dependent Degradation of the Human Estrogen Receptor. *Proc Natl Acad Sci USA* **96**:1858-1862.
- Nawaz Z, Lonard D M, Smith C L, Lev-Lehman E, Tsai S Y, Tsai M-J and O'Malley B W (1999b) The Angelman Syndrome-Associated Protein, E6-AP, Is a Coactivator for the Nuclear Hormone Receptor Superfamily. *Mol Cell Biol* **19**:1182-1189.
- Orlov I, Rochel N, Moras D and Klaholz B P (2012) Structure of the Full Human RXR/VDR Nuclear Receptor Heterodimer Complex With Its DR3 Target DNA. *EMBO J* **31**:291-300.
- Osborne CK (2012) Tamoxifen in the Treatment of Breast Cancer. *New Eng J Med* **339**:1609-1618.
- Osz J, Brélivet Y, Peluso-Iltis C, Cura V, Eiler S, Ruff M, Bourguet W, Rochel N and Moras D (2012) Structural Basis for a Molecular Allosteric Control Mechanism of Cofactor Binding to Nuclear Receptors. *PNAS* **109**:E588-E594.
- Pérez E, Bourguet W, Gronemeyer H and de Lera A R (2012) Modulation of RXR Function Through Ligand Design. *Biochimica et Biophysica Acta* **1821**:57-69.
- Pike AC, Brzozowski A M, Walton J, Hubbard R E, Thorsell A G, Li Y-L, Gustafsson J-Å and Carlquist M (2001) Structural Insights into the Mode of Action of a Pure Antiestrogen. *Structure* **9**:145-153.
- Pinkerton JV, Utian W H, Constantine G D, Olivier S and Pickar J H (2009) Relief of Vasomotor Symptoms With the Tissue-Selective Estrogen Complex Containing Bazedoxifene/Conjugated Estrogens: a Randomized, Controlled Trial. *Menopause* **16**:1116-1124.
- Qi HH, Sarkissian M, Hu G-Q, Wang Z, Bhattacharjee A, Gordon D B, Gonzales M, Lan F, Ongusaha P P, Huarte M, Yaghi N K, Lim H, Garcia B A, Brizuela L, Zhao K, Roberts T M and Shi Y (2010) The XLMR Gene PHF8 Encodes a Histone H4K20/H3K9 Demethylase and Regulates Zebrafish Brain and Craniofacial Development. *Nature* **466**:503-507.
- Roy B, Taneja R and Chambon P (1995) Synergistic Activation of Retinoic Acid (RA)-Responsive Genes and Induction of Embryonal Carcinoma Cell Differentiation by an RA Receptor α (RAR α)-, RAR β -, or RAR γ -Selective Ligand in Combination With a Retinoid X Receptor-Specific Ligand. *Mol Cell Biol* **15**:6481-6487.
- Schodin DJ, Zhuang Y, Shapiro D J and Katzenellenbogen B S (1995) Analysis of Mechanisms That Determine Dominant Negative Estrogen Receptor Effectiveness. *J Biol Chem* **270**:31163-31171.

- Schwabe JW, Chapman L, Finch J T, Rhodes D and Neuhaus D (1993a) DNA Recognition by the Oestrogen Receptor: From Solution to the Crystal. *Structure* **1**:187-204.
- Schwabe JWR, Chapman L, Finch J T and Rhodes D (1993b) The Crystal Structure of the Complex Between the Oestrogen Receptor DNA-Binding Domain and DNA at 2.4Å: How Receptors Discriminate Between Their Response Elements. *Cell* **75**:567-578.
- Shiau AK, Barstad D, Loria P M, Cheng L, Kushner P J, Agard D A and Greene G L (1998) The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen. *Cell* **95**:927-937.
- Shulman AI, Larson C, Mangelsdorf D J and Ranganathan R (2004) Structural Determinants of Allosteric Ligand Activation in RXR Heterodimers. *Cell* **116**:417-429.
- Suen C-S, Berrodin T J, Mastroeni R, Cheskis B J, Lyttle C R and Frail D E (1998) A Transcriptional Coactivator, Steroid Receptor Coactivator-3, Selectively Augments Steroid Receptor Transcriptional Activity. *J Biol Chem* **273**:27645-27653.
- Tamrazi A, Carlson K E, Daniels J R, Hurth K M and Katzenellenbogen J A (2002) Estrogen Receptor Dimerization: Ligand Binding Regulates Dimer Affinity and Dimer Dissociation Rate. *Mol Endocrinol* **16**:2706-2719.
- Thomas C and Gustafsson J-Å (2011) The Different Roles of ER Subtypes in Cancer Biology and Therapy. *Nat Rev Cancer* **11**:597-608.
- Tremblay GB, Tremblay A, Labrie F and Giguère V (1999) Dominant Activity of Activation Function 1 (AF-1) and Differential Stoichiometric Requirements for AF-1 and -2 in the Estrogen Receptor α - β Heterodimeric Complex. *Mol Cell Biol* **19**:1919-1927.
- Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker M G, Stein R B, Pike J W and McDonnell D P (1994) Human Estrogen Receptor Transactivational Capacity Is Determined by Both Cellular and Promoter Context and Mediated by Two Functionally Distinct Intramolecular Regions. *Mol Endocrinol* **8**:21-30.
- Wardell SE, Kazmin D and McDonnell D P (2012) Research Resource: Transcriptional Profiling in a Cellular Model of Breast Cancer Reveals Functional and Mechanistic Differences Between Clinically Relevant SERM and Between SERM/Estrogen Complexes. *Mol Endocrinol* **26**:1235-1248.
- Westin S, Kurokawa R, Nolte R T, Wisely G B, McInerney E M, Rose D W, Milburn M V, Rosenfeld M G and Glass C K (1998) Interactions Controlling the Assembly of Nuclear-Receptor Heterodimers and Co-Activators. *Nature* **395**:199-202.
- Willy PJ, Umesono K, Ong E S, Evans R M, Heyman R A and Mangelsdorf D J (1995) LXR, a Nuclear Receptor That Defines a Distinct Retinoid Response Pathway. *Genes and Dev* **9**:1033-1045.
- Yaghjian L and Colditz G A (2011) Estrogens in the Breast Tissue: a Systematic Review. *Cancer Causes Control* **22**:529-540.
- Zhang J, Chalmers M J, Stayrook K R, Burris L L, Wang Y, Busby S A, Pascal B D, Garcia-Ordóñez R D, Bruning J B, Istrate M A, Kojetin D J, Dodge J A, Burris T P and

MOL #84228

Griffin P R (2011) DNA Binding Alters Coactivator Interaction Surfaces of the Intact VDR-RXR Complex. *Nat Struct Mol Biol* **18**:556-563.

Footnotes

This work was supported by the National Institutes of Health Institute of Diabetes and Digestive and Kidney Diseases [Grant DK53002] and by Pfizer Pharmaceuticals.

Figure Legends

Figure 1. Activation of ER α -G521R with bazedoxifene. (A) Schematic diagram showing wild type ER α (ER α -wt) and mutant ER α (ER α -G521R) used in these experiments. ER α consists of six domains (A-F). The A/B domains contain the ligand-independent AF-1 domain, the C domain is the DNA-binding domain (DBD), D is the hinge and the EF domain encompasses the ligand binding domain (LBD). The arrow indicates the position of the G521R point mutation. (B) HepG2 cells were co-transfected with 1 μ g pC3-Luc reporter and 50 ng expression vectors for either ER α -G521R or ER α -wt. Cells were treated with the indicated concentrations of estradiol (E2), bazedoxifene (BAZ) or conjugated estrogen (CE) for 24 hr, and then harvested for luciferase assay. The activity of 10 nM E2 treated ER α -wt transfected cells was set to '100'. (C, E) HepG2 cells co-transfected with 1 μ g pC3-Luc reporter and 50 ng ER α -G521R were treated with the indicated concentrations of ligands for 24 hr. The luciferase activity of cells treated with 1000 nM BAZ (panel C) or 100 nM BAZ + 1 nM CE (panel E) was set to '100'. (D, F) HepG2 cells co-transfected with 1 μ g pC3-Luc reporter and 50 ng ER α -wt were treated with the indicated concentrations of CE or BAZ alone or in combination for 24 hr. The luciferase activity of 1 nM CE treated cells was set to a value of '100' (panels D & F). Values represent the average \pm SEM of 3 independent experiments.

Figure 2. The DNA-binding mutant ER α (G521R) activates expression of a GRE-containing reporter gene. (A) Schematic diagram showing the ERE-Luc, GRE-Luc and two chimeric reporter genes. (B) The amino acid sequence of the DNA-binding domain

(DBD) of wild type ER α and DNA-binding mutant ER α (GSCKV). The grey circles indicate the three amino acids that were mutated to enable binding to a glucocorticoid responsive element (GRE). (C) HepG2 cells co-transfected with 1 μ g of the indicated reporter genes and 50 ng expression vectors as indicated were treated with vehicle (0.1% ethanol, Veh), 10 nM E2 or 10 nM CE for 24 hr. Data are presented as relative luciferase activity to their respective vehicle-treated control. (D) HepG2 cells were co-transfected with 1 μ g EGRE-Luc and ER α -wt (25 ng), ER α (GSCKV) (25 ng) or both [25 ng ER α -wt + 25 ng ER α (GSCKV)] plasmids, and treated with vehicle or 10 nM CE for 24 hr. The luciferase activity of 10 nM CE treated ER α -wt + ER α (GSCKV) co-transfected cells was set to '100'. Values represent the average \pm SEM (n=3) for all experiments.

Figure 3. Cooperative activation of chimeric reporter gene expression by combined ER α agonist and antagonist treatment. (A & B) HepG2 cells co-transfected with 1 μ g EGRE-Luc or GERE-Luc reporter genes with 50 ng ER α -G521R, 50 ng ER α (GSCKV), or combination [25 ng ER α - G521R + 25 ng ER α (GSCKV)] of the two were treated with vehicle (0.1% ethanol), 100 nM CE, 10 nM BAZ or 100 nM CE + 10 nM BAZ for 24 hr. The luciferase activity of 100 nM CE + 10 nM BAZ treated ER α -wt + ER α (GSCKV) co-transfected cells was set to '100'. The cartoon above each graph is a schematic representation of the respective chimeric reporter gene (EGRE-Luc or GERE-Luc) and transfected forms of ER α . (C) HeLa cells were co-transfected with 1 μ g EGRE-Luc or GERE-Luc along with 5 ng ER α -G521R + 5 ng ER α (GSCKV) and treated as indicated for 24 hr. The luciferase activity of 100 nM CE+ 10 nM BAZ treated cells was set as value of

'100'. (D) HeLa cells were co-transfected with 1 μ g GERE-Luc, 5 ng ER α -G521R and 5 ng ER α (GSCKV) along with either 100 ng pCR3.1 or SRC-3 expression vector, and treated with agonist and antagonist as described above. The luciferase activity of 100 nM CE+10 nM BAZ treated pCR3.1 + ER α -wt + ER α (GSCKV) transfected cells was set to '100'. Values represent the average \pm SEM of 3 independent experiments for all luciferase assays. (E & F) Representative Western blots show the corresponding expression level of transiently transfected ER α -G521R and ER α (GSCKV), alone or in combination in HepG2 and HeLa cells. HepG2 cells were transfected with 50 ng ER α -G521R, 50 ng ER α (GSCKV), or 25 ng ER α -G521R + 25 ng ER α (GSCKV). HeLa cells were transfected with 10 ng ER α -G521R, 10 ng ER α (GSCKV), or 5 ng ER α -G521R + 5 ng ER α (GSCKV). Actin was used as loading control.

Figure 4. Ligand-regulated interaction of ER α -G521R and ER α (GSCKV). HeLa cells were transfected with 5 ng ER α -G521R-Flag and 5 ng ER α (GSCKV)-HA, either alone or in combination; pCR3.1 empty vector was added to make equal amounts of DNA for each transfection. Forty-eight hour thereafter, cells were treated with 100 nM CE + 10 nM BAZ (panel A), or vehicle, 100 nM CE, 10 nM BAZ, or 100 nM CE+ 10 nM BAZ (panel B) for 1 hr. Immunocomplexes were precipitated with anti-Flag antibody, and Western blots were performed with either Flag or HA antibody, as indicated.

Figure 5. Cooperative activation by agonist and antagonist requires receptor dimer to bind to DNA. HepG2 (panel A) and HeLa (panel B) cells co-transfected with $\frac{1}{2}$ ERE-Luc or

EGRE-Luc reporter genes as well as the indicated ER expression vectors were treated with vehicle (0.1% ethanol), 100 nM CE, 10 nM BAZ, or 100 nM CE + 10 nM BAZ for 24 hr. Data are presented as relative luciferase activity comparing to EGRE-Luc plus ER α -G521R + ER α (GSCKV) co-transfected samples treated with 100 nM CE + 10 nM BAZ. Values represent the average \pm SEM of 3 independent experiments.

Figure 6. AF1 domain is required for maximal activation by combined ER α agonist and antagonist treatment. HeLa cells were co-transfected with EGRE-Luc (panel A) or GERE-Luc (panel B) and 5 ng each of the indicated plasmids. One day after transfection, cells were treated with vehicle, 100 nM CE, 10 nM BAZ, or 100 nM CE+ 10 nM BAZ for 24 hr and harvested for luciferase assay. Data are presented as relative luciferase activity comparing to EGRE-Luc plus ER α -G521R + ER α (GSCKV) co-transfected samples treated with 100 nM CE + 10 nM BAZ. Values represent the average \pm SEM of 3 independent experiments.

Figure 7. Cooperative activation of pC3-Luc by combined ER α agonist and antagonist treatment. HepG2 cells were co-transfected with the pC3-Luc reporter gene and the indicated amounts of expression vectors for ER α -wt and ER α -G521R alone or in combination. Treatments were with vehicle, 100 nM CE, 10 nM BAZ, or 100 nM CE + 10 nM BAZ for 24 hr. The level of activity achieved with 100 nM CE alone in each transfection was set to '100'. Values represent the average \pm SEM of 3 independent experiments.

Figure 8. Different estrogens and SERMs synergistically activate chimeric reporter genes. HeLa cells were co-transfected with 1 μ g GERE-Luc reporter gene and 5 ng each of the expression vectors for ER α -G521R and ER α (GSCKV). One day after transfection, cells were treated with ER α agonist (either 100 nM CE or 100 nM E2) alone or in combination with 10 nM BAZ (panel A) or 100 nM CE alone or combined with 10 nM of the indicated SERMs (bazedoxifene, B; 4-hydroxytamoxifen, T; raloxifene, R; and ICI 182,780, I) (panel B) for 24 hr. Data are presented as relative luciferase activity comparing to 100 nM E2 + 10 nM BAZ treated samples. Values represent the average \pm SEM of 3 independent experiments. Inset in panel B, Western blot showing ER expression levels after 24 hr treatment with the indicated ligands.

Figure 1








Figure 2**A.****B.****C.****D.**



Figure 3

Figure 4

A.



B.







Figure 5

Figure 6

A.



B.




Figure 7




Figure 8

